Ironwood Pharma (IRWD) Misses Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ironwood Pharma (IRWD) Misses Q3 EPS by 5c

Ironwood Pharma's (IRWD) Linzess Sales Missed Estimates; Leerink Partners Reiterates Market Perform

November 4, 2015 9:30 AM EST

Leerink Partners maintained a Market Perform rating and $12.00 price target on Ironwood Pharmaceuticals (NASDAQ: IRWD), following the company's 3Q earnings report. IRWD reported 3Q Linzess sales of ~$117m coming in modestly below Leerink's estimate of ~$121m.

Analyst Jason Gerberry commented, "IRWD reported 3Q Linzess sales of ~$117m coming in modestly... More

Leerink Affirms Ironwood Pharma (IRWD) at 'Market Perform'; No Catalyst Seen in Next 12 - 18 Months

November 4, 2015 9:09 AM EST

Leerink affirms Ironwood Pharma (Nasdaq: IRWD) with a Market Perform rating and $12 price target following Q3 results issued Tuesday night.

Analyst Jason Gerberry commented, IRWD reported 3Q Linzess sales of ~$117 million coming in modestly below our est. of ~$121 million. The miss was modest, and we dont... More